Caris Life Sciences Study Links ESR1 L536 Mutations to Shorter Elacestrant Treatment Duration

By Public Technologies
  • Caris Life Sciences published a study in Clinical Cancer Research examining molecular differences in ESR1-mutated metastatic breast cancer.
  • Certain ESR1 variants, multiple mutations and lower estrogen receptor pathway activity were associated with shorter time on elacestrant treatment.
  • Findings suggest comprehensive molecular profiling could provide information beyond mutation status alone, but require prospective validation before guiding clinical decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk